What 'big ideas' will 2016 bring?

With 2016 just days away, various experts at the University of California-San Francisco (UCSF) were asked about the immediate future of scientific research. What diseases will we be closer to curing next year? How will science impact treatment?

For example, Atul Butte, MD, PhD, director of the UCSF Institute for Computational Sciences, thinks precision data will be able to make significant progress through using big data.

“We’re drowning in data,” Butte said. “Sitting in that data are the next drugs, the next therapeutics and the next diagnostics, waiting for us to find them.”

Meanwhile, Arnold Kriegstein, MD, PhD, director of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, predicts that organoids could have a big impact in 2016.

“There are human aspects of brain diseases that just aren’t captured by animal models," Kriegstein said. "I think patient-derived organoids are exactly what the field needs to understand what makes humans different and lead us towards cures.”

Click below to read more about these predictions, as well as others, on the university’s website:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.